Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.
Woman's World on MSN
New weight loss drug beats Ozempic and eases joint pain with 'insane' results, doctors say
The average participant getting a 12-mg weekly injection lost 71 pounds in 68 weeks. "This is beyond what we see with any ...
Pharmaceutical Technology on MSN
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
People exploring newer weight-focused therapies often ask about the Zepbound price. Cost matters because treatment plans are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback